Clelia Donisi,Andrea Pretta,Valeria Pusceddu,Pina Ziranu,Eleonora Lai,Marco Puzzoni,Stefano Mariani,Elena Massa,Clelia Madeddu,Mario Scartozzi

Abstract:Immunotherapies have revolutionized cancer treatment approaches. Because not all patients respond positively to immune therapeutic agents, it represents a challenge for scientists who strive to understand the mechanisms behind such resistance. In-depth exploration of tumor biology, using novel technologies such as omics science, can help decode the role of the tumor immune microenvironment (TIME) in producing a response to the immune blockade strategies. It can also help to identify biomarkers for patient stratification and personalized treatment. This review aims to explore these new models and highlight their possible pivotal role in changing clinical practice.

The Multi-Omics Perspective